ATC code B02 Antihemorrhagics is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. Subgroup B02 is part of the anatomical group B Blood and blood forming organs.
Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QB02. National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.
B02A Antifibrinolytics
B02AA Amino acids
B02AA01 Aminocaproic acid B02AA02 Tranexamic acid B02AA03 Aminomethylbenzoic acidB02AB Proteinase inhibitors
B02AB01 Aprotinin B02AB02 Alfa1 antitrypsin B02AB04 Camostat B02AB05 UlinastatinB02B Vitamin K and other hemostatics
B02BA Vitamin K
B02BA01 Phytomenadione B02BA02 MenadioneB02BB Fibrinogen
B02BB01 Human fibrinogenB02BC Local hemostatics
B02BC01 Absorbable gelatin sponge B02BC02 Oxidized cellulose B02BC03 Tetragalacturonic acid hydroxymethylester B02BC05 Adrenalone B02BC06 Thrombin B02BC07 Collagen B02BC08 Calcium alginate B02BC09 Epinephrine B02BC30 Combinations; e.g. Fibrin glueB02BD Blood coagulation factors
B02BD01 Coagulation factor IX, II, VII and X in combination (Prothrombin complex concentrate) B02BD02 Coagulation factor VIII B02BD03 Factor VIII inhibitor bypassing activity B02BD04 Coagulation factor IX B02BD05 Coagulation factor VII B02BD06 von Willebrand factor and coagulation factor VIII in combination B02BD07 Coagulation factor XIII B02BD08 Coagulation factor VIIa B02BD10 von Willebrand factor B02BD11 Catridecacog B02BD13 Coagulation factor X B02BD14 Susoctocog alfa B02BD15 Valoctocogene roxaparvovec B02BD16 Etranacogene dezaparvovec B02BD17 Fidanacogene elaparvovec B02BD30 ThrombinB02BX Other systemic hemostatics
B02BX01 Etamsylate B02BX02 Carbazochrome B02BX03 Batroxobin B02BX04 Romiplostim B02BX05 Eltrombopag B02BX06 Emicizumab B02BX07 Lusutrombopag B02BX08 Avatrombopag B02BX09 Fostamatinib B02BX10 Concizumab B02BX11 MarstacimabReferences
"ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis". National Institutes of Health. Retrieved 1 February 2020. https://www.nlm.nih.gov/research/umls/sourcereleasedocs/current/ATC/index.html ↩
"Anatomical Therapeutic Chemical (ATC) Classification". World Health Organization. Retrieved 3 January 2022. https://www.who.int/tools/atc-ddd-toolkit/atc-classification ↩
"Structure and principles". WHO Collaborating Centre for Drug Statistics Methodology. 15 February 2018. Retrieved 3 January 2022. https://www.whocc.no/atc/structure_and_principles/ ↩
"ATC/DDD Index 2022: code B02". WHO Collaborating Centre for Drug Statistics Methodology. http://www.whocc.no/atc_ddd_index/?code=B02 ↩
"ATCvet Index 2022: code QB02". WHO Collaborating Centre for Drug Statistics Methodology. http://www.whocc.no/atcvet/atcvet_index/?code=B02 ↩